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Loss of cell cycle control is a hallmark of cancer, which can be targeted with agents, including
Cyclin Dependent Kinase-4/6 (CDK4/6) kinase inhibitors that impinge upon the G1-S cell cycle
checkpoint via maintaining activity of the retinoblastoma tumor suppressor (RB). This class of
drugs is under clinical investigation for various solid tumor types, and has recently been FDAapproved for treatment of breast cancer. However, development of therapeutic resistance is not
uncommon. In this study, palbociclib (a CDK4/6 inhibitor) resistance was established in models of
early stage, RB-positive cancer. This study demonstrates that acquired palbociclib resistance
renders cancer cells broadly resistant to CDK4/6 inhibitors. Acquired resistance was associated
with aggressive in vitro and in vivo phenotypes, including proliferation, migration, and invasion.
Integration of RNA sequencing analysis and phospho-proteomics profiling revealed rewiring of
the kinome, with a strong enrichment for enhanced MAPK signaling across all resistance models,
which resulted in aggressive in vitro and in vivo phenotypes and pro-metastatic signaling.
However, CDK4/6 inhibitor resistant models were sensitized to MEK inhibitors, revealing reliance
on active MAPK signaling to promote tumor cell growth and invasion. In sum, these studies
identify MAPK reliance in acquired CDK4/6 inhibitor resistance that promotes aggressive disease,
while nominating MEK inhibition as putative novel therapeutic strategy to treat or prevent
CDK4/6 inhibitor resistance in cancer.

Keywords
CDK4; Cyclin Dependent Kinase; cell cycle; MAPK; ERK; kinase inhibitor; drug resistance;
prostate cancer; RB; palbociclib; ribociclib

INTRODUCTION
Author Manuscript

Dysregulation of the cell cycle is a hallmark of cancer. While initial attempts to target the
cell cycle with non-specific Cyclin Dependent Kinase (CDK) inhibitors were clinically
unsuccessful, a new generation of selective CDK4/6 inhibitors has emerged that has shown
clinical promise across multiple cancer types, including breast, melanoma and colorectal
cancer(1,2). Currently, three CDK4/6 inhibitors have entered clinical trials: palbociclib
(Ibrance), ribociclib (Kisqali) and abemaciclib(1,3). Notably, these three inhibitors have
recently received accelerated FDA-approval for treatment of hormone-receptor positive (HR
+), Her2-negative breast cancer in combination with endocrine therapy based on the
PALOMA-2 (palbociclib), the MONALEESA-2 (ribociclib), and the MONARCH-2
(abemaciclib) Phase III clinical trials(4).

Author Manuscript

Despite evidence of clinical response, development of resistance is common, and the
underlying mechanisms that lead to resistance, are poorly understood. Consistent with the
known functions of CDK4/6 in promoting cell cycle progression through phosphorylation
and inactivation of the retinoblastoma tumor suppressor protein (RB), CDK4/6 inhibitors
require an active RB pathway to elicit anti-tumor effects. As such, resistance to CDK4/6
inhibitors can occur through disruption of the RB pathway, as mediated by loss of the
retinoblastoma tumor suppressor (RB), Cyclin D1 and CDK6 amplification, and Cyclin ECDK2 activation(3,5,6). Other mechanisms of resistance have also been reported that are
independent of RB pathway alteration, including alterations or activation of the PI3K/AKT/
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mTOR pathway(7,8). Given the promise of CDK4/6 inhibitors in the clinical setting, there is
an increasing need to discern mechanisms of bypass, and identify mechanisms to anticipate
and prevent therapeutic resistance.

Author Manuscript

Therapeutic opportunities for implementation of CDK4/6 inhibitors in the clinical setting are
widest in tumors for which RB pathway disruption is infrequent or occurs late in tumor
progression. As such, studies herein were conducted using prostate adenocarcinoma (PCa)
as a tumor paradigm, in which a functional RB pathway is largely intact in early stage
disease. Prior to androgen deprivation therapy, which is the first line of therapeutic
intervention for disseminated disease, almost all tumors retain RB function, with 5% RB
loss observed in primary tumors(9). By contrast, RB loss is enriched in metastatic disease,
occurring in 37% of metastatic cases in a retrospective cohort, and in 21% of metastatic
castration-resistant prostate cancer (CRPC)(10), and is found to be causative for the
transition to CRPC(11), the lethal stage of disease. Thus, CDK4/6 inhibitors are under
clinical testing in both hormone-naïve metastatic PCa (NCT02059213) and metastatic CRPC
(NCT02555189) as adjuvant therapy for first- and second-line hormone therapy,
respectively.

Author Manuscript

As shown herein, acquired palbociclib resistance not only rendered cancer cells broadly
resistant to CDK4/6 inhibitors, but also promoted aggressive phenotypes, including
accelerated growth in vitro and in vivo, as well as enhanced invasion and clonogenic
capacity. Unbiased global gene expression and phosphoproteomic profiling were utilized to
interrogate the molecular alterations of acquired resistance to CDK4/6 inhibition in multiple
models of palbociclib resistance. These integrated approaches revealed a reduction of RB
function resulting in CDK4/6 inhibitor resistance. Additionally, acquired CDK4/6 resistance
was associated with activation of the MAPK signaling pathway, which conferred
sensitization to MEK inhibitors. In sum, these studies demonstrate partially retained,
hyperphosphorylated Rb in acquired CDK4/6 inhibitor resistance, and nominate MEK
inhibitors as a new treatment strategy for advanced cancers upon developing CDK4/6
inhibitor resistance.

MATERIALS AND METHODS
Tissue culture and establishing resistance lines

Author Manuscript

LNCaP and LAPC4-derived cells were cultured in improved minimum essential media
(IMEM; Corning, Manassis, VA) or Iscove’s modified Dulbecco media (IMDM; Corning,
Manassis, VA), respectively, supplemented with 5% heat-inactivated fetal bovine serum
(FBS; HyClone, USA), 1% L-glutamine and 1% penicillin/streptomycin(11). Unless
otherwise described, cells were plated overnight, and treated with 0.5μM PD0233991 (PD,
palbociclib, SelleckChem), LEE011 (LEE, ribociclib, Novartis) or U0126 (Promega).
Palbociclib resistant cell models were generated from LNCaP and LAPC4 cells by sustained
treatment with 0.5μM PD (Schematic in Figure 1A), and maintained under selection when
resistance, measured via BrdU incorporation, was achieved after ~3 months. Cells were
authenticated by ATCC and checked for mycoplasma upon thawing and at termination of
maintenance after <20 passages (ATCC 30-1012K).
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Cells were treated with a dose range of indicated doses of PD, LEE or U0126 for up to 6
days, with drugs refreshed every other day. Cells were trypsinized, counted twice on a
hemacytometer using the Trypan blue exclusion method, normalized to a drug-free control.
Experiments were performed at least twice in quadruplicate.
Flow Cytometry

Author Manuscript

Cells were treated with 0.5μM PD or LEE for 24h, and after a 2-hour pulse labeling of
bromodeoxyuridine (BrdU; Amersham, RPN201), adherent cells were harvested and fixed
with 100% ethanol. Proliferation was measured by bivariate flow cytometry using BrdU and
propidium-iodide (PI) staining. A Millipore Guava EasyCyte flow cytometer captured
10,000 BrdU/PI events and the Millipore InCyte software was used to gate for the
percentage of BrdU incorporation. Experiments were performed at least twice in biological
triplicate.
RT-PCR
Cells were treated with 0.5μM PD or CTRL for 24h, and processed to assess RB1
expression, as described previously(12), performed at least twice in biological triplicate.
Immunoblotting

Author Manuscript

Protein harvesting and immunoblotting were performed as previously described(12),
quantified in ImageJ. Antibodies used are mouse-α-RB (BD-Biosciences, 554136), rabbitα-GAPDH (Santa Cruz, SC-25778), rabbit-α-CyclinA (Santa Cruz, SC-596), rabbit-αERK1 (Santa Cruz, SC-94), rabbit-α-phospho-p44/p42(T202/Y204) (Cell Signaling,
4370S), goat-α-LaminB (Santa Cruz, SC-6217). Phospho-blots were blocked and
immunoblotted in 2.5% BSA, all other blots with 5% milk in PBS-Tween.
Migration and Invasion Assays
Corning FluoroBlok 24-Multiwell and Corning BioCoat Tumor Invasion System plates were
utilized for migration and invasion assays, according to protocols provided by the company,
performed at least twice in quadruplicate. Bottom wells were filled with IMEM/20%FBS.
50,000 cells (passed 2x, 40um cell strainers) were seeded in the top compartment of each
well in serum-free IMEM and incubated for 48h (migration) or 72h (invasion). Cells were
stained with Corning Calcein AM Fluorescent Dye and measured on a BioTek SynergyHT
plate reader.

Author Manuscript

Clonogenic Assays and FIJI
The bottom layer of 1% agar/PBS was mixed 1:1 with culture media supplemented with
20% FBS and poured into 6-well plates, after which a second layer with 0.6% agar/FBS
mixed with a cell-media/20%FBS suspension was poured on top. Where mentioned, drugs
were mixed into both agar layers. 200ul media +/− drugs was added on top and refreshed
twice a week. 5000 cells were seeded per well in triplicate. Plates were incubated for 3
weeks, after which each well was photographed. Images were analyzed with FIJI (ImageJ)
as follows: select each well transform to gray scale, adjust the threshold to remove

Clin Cancer Res. Author manuscript; available in PMC 2019 September 01.

de Leeuw et al.

Page 5

Author Manuscript

background, and detect colonies, Analyze Particles to count total colonies and pixel sizes of
each colony. Experiments were performed at least twice in triplicate.
In vivo studies
Xenograft studies were performed in accordance with NIH Guidelines and animal protocols
were approved by IACUC at Thomas Jefferson University. Cells (3×106 per injection)
suspended in PBS were combined 1:1 with Matrigel (BD Biosciences, 354234) and injected
subcutaneously into the flanks of 5-6-week-old, intact-male athymic nude mice (Charles
River Laboratories). Tumor development was monitored over time by palpation. Where
indicated, mice received AIN-76A diet laced with 6.7mg/kg trametinib or control (kindly
provided by the laboratory of Dr Andrew Aplin, Thomas Jefferson University).
RNA sequencing (RNAseq) and GSEA analyses

Author Manuscript
Author Manuscript

RNA was extracted with the RNeasy kit (Qiagen) from PDR and parental LNCaP or LAPC4
cells pre-treated 24h with 0.5μM PD or vehicle (CTRL). 100-200 ng of total RNA was used
to prepare RNAseq libraries using the TruSeq RNA Sample Prep Kit V2 (Illumina, San
Diego, CA), following the protocol described by the manufacturer. High throughput
sequencing (HTS) was performed using an Illumina HiSeq2500 with each sample sequenced
to a minimum depth of ~50 million reads. A paired end 2×125 cycle sequencing strategy
was employed. Data were subjected to Illumina quality control (QC) procedures (>80% of
the data yielded a Phred score of 30). Secondary analysis was carried out on an OnRamp
Bioinformatics Genomics Research Platform (OnRamp Bioinformatics, San Diego, CA)
(13). OnRamp’s advanced Genomics Analysis Engine utilized an automated RNAseq
workflow to process the data(13,14), including (1) data validation and quality control, (2)
read alignment to the human genome (hg19) using TopHat2(15), which revealed >90%
mapping of the paired end reads, (3) generation of gene-level count data with HTSeq, and
(4) differential expression analysis with DEseq2(15), which enabled the inference of
differential signals with robust statistical power. (Genomics Research Platform with RNAseq
workflow v1.0.1, including FastQValidator v0.1.1a, Fastqc v0.11.3, Bowtie2 v2.1.0,
TopHat2 v2.0.9, HTSeq v0.6.0, DEseq v1.8.0).

Author Manuscript

The resulting BAM files were sorted and inputted into the Python package HTSeq to
generate count data for gene-level differential expression analyses. To infer differential
signal within the data sets with robust statistical power, DEseq2 was utilized(15). Transcript
count data from DESeq2 analysis of the samples were sorted according to their adjusted pvalue or q-value, the smallest false discovery rate (FDR) at which a transcript is called
significant (q<0.1). FDR is the expected fraction of false positive tests among significant
tests and was calculated using the Benjamini-Hochberg multiple testing adjustment
procedure. LNCaP (LN) and LAPC4 (L4) sequencing data are deposited NCBI’s Gene
Expression Omnibus(16), accessible through GEO Series accession number GSE99675.
Analysis of Phosphotyrosine, Phosphoserine and Phosphothreonine Peptides by
Quantitative Mass Spectrometry
PDR and parental LNCaP or LAPC4 cells were treated 24h with 0.5μM PD or CTRL,
scraped, pelleted, and snap frozen. Protein digestion and phosphopeptide enrichment were
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performed as previously described(17–19) with minor modifications. Briefly, cells were
lysed in 6M guanidinium hydrochloride buffer (6M Guanidinium chloride, 100mM Tris
pH8.5, 10mM Tris (2-carboxyethyl) phosphine, 40mM 2-chloroacetamide, 2mM Vanadate,
2.5mM NaPyrophosphate, 1mM Beta-glycerophosphate, 10mg/ml N-octyl-glycoside).
Lysates were sonicated, cleared, and protein was measured. 5 mg of protein was digested
with trypsin and the resulting phosphopeptides were subjected to phosphotyrosine antibodybased enrichment via immunoprecipitation. The immunoprecipitate was washed and
phospho-Tyrosine (pY) peptides were eluted. The supernatant from the pY
immunoprecipitations was kept for phospho-Serine/Threonine (pST) peptide enrichment. 2.5
mg of pST peptides were de-salted using C18 columns and then separated using strong
cation exchange chromatography. In separate reactions the pY and pST peptides were then
further enriched using titanium dioxide columns to remove existing non-phosphorylated
peptides. The pY and pST peptides were then de-salted using C18 tips prior to submission
on the mass spectrometer. Samples were analyzed by LC-MS/MS using a dual pump
nanoRSLC system (Dionex, Sunnyvale CA) interfaced with a Q Exactive HF
(ThermoFisher, San Jose, CA). Samples were run in technical duplicates, and data were
searched using MaxQuant Andromeda version 1.5.3.30(20) against the Uniprot human
reference proteome database with canonical and isoform sequences (downloaded September
2016 from http://uniprot.org). MaxQuant Andromeda parameters were set as previously
described(21). Data are deposited in the ProteomeXchange Consortion via the PRIDE
partner repository, accessible through dataset identifier PXD006561(22).

Author Manuscript
Author Manuscript

MS data analysis was performed as previously described(23). For clustering, pY data were
filtered using an FDR-corrected ANOVA p-value of 0.2, pS/pT data were filtered using an
FDR-corrected ANOVA p-value of 0.05. Hierarchical clustering was performed using the
Cluster version 3.0 with the Pearson correlation and pairwise complete linkage analysis(24).
Java TreeView version 1.1.6r4 was used to visualize clustering results(25).
Kinase Substrate Enrichment Analysis (KSEA)

Author Manuscript

KSEA was performed as previously described(18). Briefly, phosphopeptides were rankordered by average fold change between PDR and parental cells. The enrichment score was
calculated using the Kolmogorov-Smirnov statistic. Statistical significance was calculated
via permutation analysis. The normalized enrichment score (NES) was calculated by taking
the enrichment score and dividing by the mean of the absolute values of all enrichment
scores from the permutation analysis. The Benjamini-Hochberg procedure was utilized to
calculate false discovery rate for each kinase. For pY analyses, cutoffs of FDR<0.05, hits>4,
and NES>1.3 were used. For pST analyses, cutoffs of FDR<0.02, hits>5, and NES>2 were
used.

RESULTS
While CDK4/6 inhibitors have shown promise in clinical trials for cancer treatment,
acquired resistance is common. Thus, the present study interrogated the underpinnings of
therapeutic resistance, to identify markers for therapeutic outcome and develop new
strategies when resistance develops.
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Palbociclib-resistant (PDR) PCa cell models generated from hormone-therapy sensitive PCa
cells (LNCaP and LAPC4) demonstrated retained BrdU incorporation after PD treatment
(LNCaP-parental: 5.3%; LN-PDR1: 32.3%; LN-PDR2: 34.2%), indicative of a G1/S cell
cycle checkpoint bypass (Figure 1A, Supplementary Figure 1A). Retained Cyclin A (an
RB/E2F target gene) protein levels after 24 hours treatment with 0.5 μM PD confirmed
acquired resistance (Figure 1B, Supplementary Figure 1B). Ribociclib (LEE011, LEE) is
similar to PD in chemical structure and likewise targets the ATP binding pocket, and thus it
was not surprising that the PDR models were resistant to LEE, as observed via retained
BrdU incorporation (LNCaP-parental: 9.8%; LN-PDR1: 35.4%, LN-PDR2: 37.9%) and
Cyclin A (Figure 1A/B, Supplementary Figure 1A/B). Dose response curves confirmed that
PDR models continued to proliferate, while the parental cells were arrested at submicromolar doses of PD or LEE (Figure 1C/D). These findings indicate that acquired
resistance to palbociclib confers broad resistance to this class of agents, suggestive of
common mechanisms of bypass.
Acquired CDK4/6 inhibitor resistance is associated with rewired transcriptional programs

Author Manuscript

To identify transcriptional alterations underlying CDK4/6 inhibitor resistance, PDR and
parental cells were treated for 24 hours with 0.5μM PD or control (CTRL), and RNA
sequencing was performed. The MA plots in Supplementary Figures 2A (right) and 3A
represent the log ratio (M) of the PD versus CTRL values over the average log intensity (A)
of each transcript, visualizing a global reduction of differentially expressed genes in PDR
models compared to the parental cells after PD treatment. Strikingly, the large cluster of
downregulated genes in the parental model (indicated by the blue arrow) was absent in the
resistant cells, confirming that PD is unable to significantly inhibit this gene cluster. When
comparing PDR1 and PDR2 profiles to parental cells, in both PD-treated and CTRL
conditions, vast transcriptomic changes were observed in both the total number of
differentially expressed transcripts and log ratio amplitudes (Figure 2A, left, Supplementary
Figure 3B). While PD treatment showed limited impact on the transcriptome of the PDR
lines compared to parental cells, these models demonstrated extensive alteration in the
transcriptome to adapt to extended PD exposure. The majority of transcripts (>1.5-fold, qvalue<0.1) were common between the two independently generated LNCaP PDR models in
both CTRL and PD conditions (Figure 2A, right). Although the PDR models showed a few
distinctions, deregulated signaling pathways common between PDR models are most likely
to contribute to resistance.

Author Manuscript

To identify common pathways enriched in the PDR models, complete transcriptional profiles
were utilized in Gene Set Enrichment Analyses (GSEA: www.broadinstitute.org/GSEA)
interrogating the predefined Oncogenic Signatures and Hallmarks from the Molecular
Signature Database (MSigDB) (Figure 2B; Supplementary Figures 2B/3D). Gene sets
enriched in both PDR models under at least one condition were selected to highlight
pathways that are most likely to contribute to acquired CDK4/6 inhibitor resistance.
Enriched Hallmark gene sets included G2M Checkpoint, supporting the contention that
resistant cells bypass the G1/S checkpoint and progress through cell cycle. Enrichment of
E2F Targets in PDR lines suggests increased E2F activity, potentially mediated through a
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bypass of RB. Genomic RB loss has been observed in ~30% of advanced PCa across
different patient cohorts, and as RB is the main target of CDK4/6-mediated phosphorylation,
loss of this gene has been attributed to resistance to CDK4/6 inhibitors(5,26). Concordantly,
RB knockdown Oncogenic Signatures were also enriched, further highlighting that RB
function may be reduced (Figure 2B). RT-PCR and immunoblotting demonstrated that total
RB mRNA and protein were retained in all PDR lines, albeit reduced to 29-56%
(Supplementary Figures 2C/3C top). Retained RB protein in the PDR models remained
hyperphosphorylated (Supplementary Figures 2C/3C bottom, upper band total RB (tRB)) in
presence of a CDK4/6 inhibitor, which attenuates RB function, confirming aberrant
inactivation of RB in presence of CDK4/6 inhibitors that likely causes bypass of the G1/S
checkpoint and activation of E2F transcription factors. As the kinome forms an intricate
network of interactions(27), it was postulated that bypass of CDK4/6 inhibition likely causes
kinome rewiring. Notably, RNA sequencing uncovered enrichment of numerous kinase
related signatures (Figure 2B/C, Supplementary Figure 4A). These findings served as the
impetus for further exploration to identify specific kinase pathway(s) that could present
novel targets for therapeutic intervention.
MAPK activation is a hallmark for CDK4/6 inhibitor resistance

Author Manuscript
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Phosphoproteomic mass spectrometry profiling provided an unbiased approach to
investigate the PDR-associated kinome. Cells were treated for 24h with either 0.5μM PD or
control, lysed and digested (Figure 3A). Phospho-Tyrosine (pY) peptides were
immunoprecipitated with an anti-pY antibody, while phospho-Serine/Threonine peptides
(pST) remained in the supernatant, allowing analysis of both peptide populations via Liquid
Chromatography with tandem Mass Spectrometry (LC-MS/MS)(23). Hierarchical clustering
revealed altered phosphorylation levels of peptides across models and treatments, while
duplicate samples cluster together (Figure 3A, Supplementary Figure 4B). Phospho-peptide
profiles were subjected to kinase substrate enrichment analyses (KSEA). The pY peptides
unveiled multiple motifs targeted by Src and its SH2-domain (Figure 3B, Supplementary
Figure 4C), which is linked to cancer progression(28). The pST peptides were strongly
enriched for motifs targeted by ERK1 and ERK2 (aka MAPK3 and MAPK1; Figure 3C,
Supplementary Figure 4D). To prioritize changes in the phosphoproteome most likely to link
to CDK4/6 inhibitor resistance, results were compared with the gene expression data.
Intriguingly, KRAS and RAF kinases, both of which were highly represented in the
Oncogenic Signatures from the RNAseq data, regulate ERK1/2 via Mitogen-Activated
Protein Kinase Kinase, or MEK(29). These data suggest that kinase-signaling cascades play
an important role in acquired CDK4/6 inhibitor resistance in these models. Moreover, the
MAPK pathway is targetable with clinically tested pharmacologic agents, such as MEK
inhibitors that are already FDA-approved for some cancers (e.g. melanoma)(29), nominating
this pathway for further study. Together, these data indicate that acquired resistance to
CDK4/6 inhibitors was associated with induced MAPK pathway activity.
Activated ERK is associated with aggressive phenotypes
As described above, Oncogenic Signatures representative of altered KRAS and RAF
signaling were highly enriched as a function of acquired CDK4/6 inhibitor resistance. KRAS
acts upstream of RAF family kinases, regulating their activity, and in turn the RAF family
Clin Cancer Res. Author manuscript; available in PMC 2019 September 01.
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kinases directly activate ERK1/2 kinases through phosphorylation(29). Indeed, while overall
ERK1/2 levels were unchanged, ERK1/2 kinases were hyper-phosphorylated in the
resistance models (Figure 4A, Supplementary Figure 5A), which would explain the
observation that ERK1/2 motifs are differentially phosphorylated in the phosphoproteomics
analysis. While canonical MAPK activating growth factor receptors (EGFR and FGFR
families(30)) displayed no consensus in differential expression, EGF transcripts were
consistently upregulated in the PDR models, which was associated with altered EGFR
activity in the phosphoproteomic data (Figure 3B and Suppl. Figure 4C). Elevated EGF
protein levels were confirmed via western blotting, which likely causes MAPK activation in
these models (Figure 4B, Supplementary Figure 5B). Combined, these data strongly suggest
that acquired CDK4/6 inhibitor resistance results in increased EGF production, leading to
hyperactivation of the MAPK pathway.

Author Manuscript
Author Manuscript

As activated MAPK signaling is known to induce proliferation via induction of D-type
Cyclins and prevent apoptosis, and thus can drive cancer progression(29,31–33), the PDR
models were further characterized biologically. Baseline growth (off PD selection) was
compared to the parental cells, demonstrating an almost three-fold higher growth rate for the
LNCaP-derived models (Figure 4C; no growth difference was observed for LAPC4 cells,
data not shown). Trans-well chemotaxis assays from 0% to 20% serum conditions revealed
an increased migratory capacity and enhanced invasion in the PDR models (Figure 4D,
Supplementary Figure 5C). Consonantly, transcriptome data revealed enrichment of the
GSEA Hallmark for Epithelial Mesenchymal Transition (EMT) in the PDR lines
(Supplementary Figure 2D/3E), which could underlie the aggressive, migratory and invasive
characteristics these models have obtained upon acquiring PD resistance. To assess
clonogenic growth capacity, cells were suspended at low density in agar-containing culture
media and incubated for three weeks to allow colony formation. HRAS-transformed Mouse
Adult Fibroblasts (MAF cells) served as a positive control due to previously described
capacity to grow 3D colonies(34). Representative images of culture wells for each cell line
are shown in Figure 4E (left). To utilize an unbiased approach for colony formation
analyses, a macro was developed for FIJI (ImageJ), which counts total colonies per well and
measures the pixel size of each colony. Although there was no significant difference in total
colonies formed by the LN-PDR or parental LNCaP cells (Supplementary Figure 5D; note
that LAPC4 and derivatives did not form colonies after >1 month), median colony sizes in
the LN-PDR1 and LN-PDR2 models were significantly larger than the parental cells
(p=0.0008 and p=0.0001 respectively, One-way ANOVA; Figure 4E, right). Combined, these
findings reveal that acquired resistance to CDK4/6 inhibitors is associated with phenotypes
linked to aggressive tumor behavior.

Author Manuscript

To challenge these concepts in vivo, cells were injected subcutaneously on the flanks of
athymic nude mice (n=6 per group) and monitored over time for tumor take. Strikingly, the
PDR models reached a 50% tumor take after only 13-14 days, while the first parental tumor
formed after 20 days, and a 50% tumor take was not reached until 47 days post-injection.
Moreover, 100% of the mice injected with PDR cells formed palpable tumors, compared to
only 67% in the parental model (Figure 4F). Combined, acquired CDK4/6 inhibitor
resistance is associated with hyperproliferation, enhanced migration and invasion, enlarged
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colonies, and accelerated, more efficient in vivo tumor take, thus promoting aggressive
tumor phenotypes.
Acquired CDK4/6i resistance leads to dependence on MAPK signaling

Author Manuscript

With clinical trials testing a MEK inhibitor already underway for PCa (trametinib:
NCT01990196, NCT02881242), and the observation that the direct downstream targets of
MEK (i.e. ERK1/2) are hyperactivated upon CDK4/6 inhibitor resistance, the PDR models
were assessed for sensitization to MEK inhibition. Cells treated overnight with a pre-clinical
MEK inhibitor (U0126) showed reduction in phosphorylation of ERK1/2, the primary target
proteins for MEK kinases (Figure 5A, Supplementary Figure 6A). To assess sensitivity to
MEK inhibition, cells were treated for 6 days with U0126, and quantified via Trypan blue
exclusion, demonstrating that the CDK4/6 inhibitor resistant cells are sensitized to MEK
inhibition (Figure 5B, Supplementary Figure 6B). Additionally, MEK inhibition reduced the
invasion capacity of the PDR lines, whereas the parental cells were unresponsive (Figure
5C). The MEK inhibitor hampered the clonogenic capacity in the PDR models, reducing not
only the size of the colonies, but also total numbers of colonies formed, while the parental
cells were not affected (Figure 5D). Combining MEK and CDK4/6 inhibitors resulted in a
cooperative effect (Figure 5E). Sensitization to MEK inhibition was validated in vivo
(Figure 5F), wherein mice with palpable xenograft tumors received a diet laced with
trametinib (6.7mg/kg AIN-76A diet) or control diet (AIN-76A). These data demonstrated
that tumor growth of the CDK4/6 inhibitor resistant models was reduced, while parental
tumors were unresponsive. Together, these findings suggests that activation of the MAPK
pathway not only promotes cell growth in the PDR models, but also the more aggressive,
invasive phenotypes observed. Additionally, the CDK4/6i resistant cells appear to have
become more reliant on MAPK signaling and as such are sensitized to MEK inhibition.

Author Manuscript
Author Manuscript

Although KRAS activating mutations are not commonly observed in PCa, the MAPK
pathway can be activated via other mechanisms, such as RAF fusions and
overexpression(35). To investigate the clinical relevance of potential MAPK activation in
prostate cancer, human primary PCa (TCGA(36)) and metastatic CRPC (SU2C/PCF(10))
datasets were interrogated for alterations of the following components of the MAPK
signaling pathway (Figure 6AB): RAS family (KRAS, HRAS, NRAS), RAF family (c-RAF/
RAF1, ARAF, BRAF), MEK family (MAP2K1, MAP2K2) and ERK1/2 (or MAPK3 and
MAPK1). The primary PCa dataset displayed alterations (mutations, CNA, mRNA z-score:
2.0) in any of these kinases in 38% of all patients, the majority of which were mRNA
upregulation (Figure 6A/B, Supplementary Figure 7). The frequency of MAPK related
upregulation was confirmed in the metastatic CRPC cohort, in which 47% presented with
alterations, including RAF amplifications and gene fusions that may lead to MAPK
activation. Interestingly, RAF alterations are more common than RAS perturbations in either
cohort (Figure 6B). Taken together, data herein suggest that acquired CDK4/6 inhibitor
resistance is associated with reduced RB expression and loss of function, and this coincides
with MAPK activation that may bypass CDK4/6-RB signaling to induce phenotypes of
aggressive features and metastasis; however, this dependence confers sensitivity to MEK
inhibitors that may be exploited therapeutically.
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Discussion
CDK4/6 inhibitors have shown clinical benefit in multiple tumor types, including breast
cancer; however, these agents are unlikely to provide a durable cure, and development of
resistance is anticipated. Studies herein developed pre-clinical models of CDK4/6 inhibitor
resistance to identify major mechanisms and consequences of CDK4/6 bypass, wherein: i)
Acquired resistance to palbociclib resulted in broad CDK4/6 inhibitor resistance; ii)
Resistance was associated with MAPK activation, which iii) conferred aggressive in vitro
and in vivo phenotypes; and iv) MAPK-activated, CDK4/6 inhibitor resistant cancer cells are
sensitized to MEK inhibitors. In summary, these studies identify MAPK induction in
acquired CDK4/6 inhibitor resistance, and nominate MEK inhibitors as a means to either to
prevent or treat CDK4/6 inhibitor resistant cancer.
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Several previous reports have approached CDK4/6 inhibitor resistance in various cancers
from different perspectives, including clinical correlations with genetic alterations(6),
correlation of RB loss of function gene signature(37), and an siRNA screen identifying
PDK1 by targeting the whole kinome(7), which was not observed in the current study. To
date, few studies have reported on acquired resistance modeling(8,26,31,38), which largely
focused on genomic alterations, gene amplifications or deletions that could lead to CDK4/6
inhibitor resistance (including RB1 loss and other aberrations in the CDK4/6-RB pathway).
Although the observed genetic alterations are poised to affect CDK4/6 inhibitor efficacy,
these may not reflect the molecular underpinnings of disease progression in patients that
initially respond. Data herein suggest that cancer cells acquired resistance through aberrant
inactivation of retained (albeit reduced) RB protein, likely via rewiring of the kinome to
bypass CDK4/6 inhibition. Induction of the MAPK pathway was observed in CDK4/6
inhibitor resistance, determined by comparing phosphoproteomic and transcriptomic data
and selecting alterations observed across PDR models. While genomic and functional RB
loss are associated with poor cancer outcomes(39) and progression to castration resistance in
the context of PCa(11,12,40), the role for MAPK signaling in regulation of RB remains
somewhat elusive. MAPK controls expression and function of D-type Cyclins, and CDK4/6
requires direct binding to D-type Cyclins to exert kinase function and phosphorylate RB, and
therefore it could be speculated that the observed elevated MAPK signaling bypasses
CDK4/6 inhibitors via Cyclin D (Figure 6C). Cyclin D1 elevation has been linked to early
adaptation to palbociclib in breast cancer models, where it induced a non-canonical Cyclin
D1/CDK2 complex that restored RB phosphorylation under CDK4/6 inhibition(8). However,
the CDK4/6 inhibitor resistant models presented herein displayed no change in Cyclin D1
levels (data not shown), and MEK inhibition did not affect hyperphosphorylation of RB
(Figure 5A, Supplementary Figure 6A), demonstrating that MAPK activation does not
mediate CDK4/6 inhbitor resistance directly, but likely presents a kinome bypass to promote
tumor progression. Some studies have demonstrated intrinsic insensitivity to CDK4/6
inhibitors in cancer models with MAPK-activating mutations(41). Whole Exome
Sequencing revealed no reproducible alterations (data not shown), and none had relevance to
MAPK signaling. Taken together, non-genomic MAPK activation, e.g. through upregulation
of EGF observed in these models, likely mediates acquired resistance.
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MAPK was identified as a major factor in kinome rewiring upon acquired CDK4/6 inhibitor
resistance, and associated with aggressive tumor phenotypes in vitro and in vivo. Activated
MAPK signaling has been previously shown to promote prometastatic signaling and
EMT(42). Invasion was attributed to ATF-2-mediated MMP-2 activation across various
cancer models, including prostate(43). Moreover, MAPK activation has been associated with
advanced stages of solid tumors (e.g. prostate, breast, lung)(43), and therefore it is not
surprising that the PDR models displayed more aggressive phenotypes than the parental
cells, and thus it is crucial to identify vulnerabilities of disease that progresses on CDK4/6
inhibitors, and develop alternative treatment regimens. Strikingly, activation of the MAPK
pathway sensitized the CDK4/6 inhibitor resistant cells to MEK inhibition, providing new
rationale for testing MEK inhibitors in advanced prostate and other cancers that do not
necessarily activate MAPK via classical KRAS mutations or RAF fusions. Moreover,
phospho-ERK1/2, indicative of MAPK activity, can be determined via immuno-labeling in
clinical specimens from clinical trials (NCT02881242). It would be of interest to explore
phospho-ERK1/2 as a clinical biomarker for resistance to CDK4/6 inhibitors. Alternatively,
CDKs and MAPKs are known to form complex kinase networks that interact and regulate
cellular processes involved in cell growth and death(27), and thus targeting these two nodes
of the kinome would provide a novel opportunity for therapeutic intervention that could
extend CDK4/6 inhibitor response or potentially prevent resistance altogether. These drug
combinations are demonstrated to synergize in models of colorectal cancer(33),
neuroblastoma(41), and even in MEK-inhibitor-resistant melanoma models(32,44). BRAFinhibitor-resistant melanoma may still respond to CDK4/6 inhibitors combined with mTOR
inhibitors(45). One activated-RAS melanoma study shows MEK and CDK4/6 inhibitors
target complementary downstream networks inducing apoptosis and cell cycle arrest,
causing in vivo tumor regression(46). KRAS-mutant non-small-cell lung cancer patients
showed improved progression-free survival on palbociclib and a MEK inhibitor
(PD-0325901)(47). Considering the cooperative effect of a CDK4/6 and MEK inhibitor
observed in the PDR models, these combinations merit prioritization for further preclinical
cancer studies with the potential for future clinical trial development, either upfront to delay
onset of CDK4/6 inhibitor resistance or when cancer progresses. As trametinib has already
entered clinical trials in PCa (NCT02881242), and has been FDA-approved for
melanoma(44), its clinical application could be considered in the context of CDK4/6
inhibitor resistance.
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Clinically, MEK inhibitors are likely to be combined with AR signaling targeted
therapeutics (e.g. enzalutamide). Interestingly, the PDR models herein display a deenrichment of the Androgen Response Hallmark signature, suggesting a reduced reliance on
AR, which could result in castration resistance. Therefore, it is paramount to assess whether
acquired CDK4/6 inhibitor resistance can lead to enzalutamide resistance, and whether this
can be circumvented with the addition of a MEK inhibitor, to define optimal strategies for
clinical implementation.
While induction of MAPK signaling, associated with aggressive phenotypes, was commonly
observed across the PDR models, this does not rule out that other kinases identified in either
of the RNAseq and phosphoproteomics datasets may contribute to the development of
resistance and cancer progression. Notably, Src motifs were highly enriched in the
Clin Cancer Res. Author manuscript; available in PMC 2019 September 01.

de Leeuw et al.

Page 13

Author Manuscript

phosphoproteomic data alone, yet Src kinase is known to impinge on CyclinD/CDK4, and is
an actionable target for which clinical agents (i.e. dasatinib) have already been
developed(28). Although dasatinib in combination with abiraterone did not improve
progression free survival in metastatic CRPC(48), it merits further preclinical investigation
in the context of CDK4/6 inhibitor resistance with the potential for additional therapeutic
application.
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In summary, the findings presented demonstrate that acquired CDK4/6 inhibitor resistance
resulted in a kinome rewiring that not only promotes therapeutic resistance, but conferred
aggressive phenotypes associated with tumor cell proliferation and invasion. Mechanistic
investigation identified a reliance on MAPK activation, and therefore nominates the MAPK
signaling pathway as a potential therapeutic target for tumors bypassing CDK4/6 inhibition.
These collective observations not only provide insight into the molecular underpinnings of
acquired resistance to cell cycle targeted therapies, but provide the basis for the next line of
pre-clinical investigation, and a rationale to develop novel combinatorial or sequential
therapeutic strategies in the clinic.
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TRANSLATIONAL RELEVANCE
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In light of recent successes with the clinical application of Cyclin Dependent Kinase-4/6
(CDK4/6) inhibitors in breast cancer and with clinical trials underway in multiple tumor
types, it is anticipated that this class of drugs will become standard of care for a variety of
malignancies. Unfortunately, development of therapeutic resistance is common, and
therefore it is imperative to understand mechanisms allowing cancer progression. This
study demonstrates in preclinical models that acquired CDK4/6 inhibitor resistance is
associated with a rewired kinome, which includes activation of the MAPK signaling
pathway as a common occurrence across models, which conferred aggressive in vitro
phenotypes, pro-metastatic signaling, and enhanced tumor take in vivo. However, this
MAPK signaling dependence resulted in sensitization to MEK inhibitors, nominating
MEK inhibition as a potential therapeutic approach to treat CDK4/6 inhibitor resistant
cancers.
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Figure 1. Acquired resistance to palbociclib results in broad CDK4/6 inhibitor resistance

A. Palbociclib (PD) resistant (PDR) prostate cancer cells were generated via continuous
selection with 0.5μM PD for 2-3 months and evaluated regularly via flow cytometry (top).
PD resistance was determined by treating biological triplicate parental or PDR cells with
0.5μM PD, LEE (ribociclib), or CTRL (no drug) for 24h and measuring BrdU incorporation
with a flow cytometer after a 2 hour pulse labeling, fixation in EtOH and staining with a
secondary FITC-mouse-anti-BrdU antibody. FACS analysis was performed by gating for the
BrdU+ S-phase population (representative flow traces for biological triplicates are shown on
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the left), quantified in a bar graph on the right as an indication of cell proliferation. FACS
analysis showed that PD and ribociclib (LEE) fail to induce cell cycle arrest in the G1-phase
in LNCaP PDR lines. B. Cells were treated for 24h with CTRL, 0.5μM PD, or LEE and
immunoblotted for Cyclin A, demonstrating a reduction in Cyclin A protein upon exposure
to PD or LEE only in the parental cells, indicating biochemical resistance in LNCaP PDR
cells. C. Cell counting via Trypan blue exclusion of quadruplet samples with dose escalation
treatment with PD of t=6 days (LNCaP) or t=13 days (LAPC4) shows a significantly
reduced response to PD in the PDR models, compared to the parental cells. D. Acquired
resistance to PD results in broad CDK4/6 inhibitor resistance as shown by a LEE dose
escalation. *Significance for dose response curves was determined by a Two-way ANOVA
analysis performing a multivariate comparison of mean per dose for PDR vs parental data.
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Figure 2. Acquired CDK4/6 inhibitor resistance is associated with rewired transcriptional
programs including RB function

A. RNAseq was performed on PDR1/2 and parental LNCaP cells treated 24h with 0.5μM
PD or vehicle (CTRL). The MA plots (right) represent the log ratio (M) of PDR versus
parental values over the average log intensity (A) of each transcript, which visualizes vast
differences between the PDR vs parental data (red dots and inset numbers indicate
significant hits, q-value<0.1). Venn diagrams show overlap between PDR1 and PDR2 of
genes >1.5x differentially expressed compared to the parental cells (q-value<0.1; right). B.
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The complete RNAseq profiles for each PDR vs parental model comparison were subjected
to unbiased Gene Set Enrichment Analysis (GSEA, MSigDB) to determine enrichment of
predefined Oncogenic Signatures in both PDR1 and PDR2 compared to parental cells under
at least one condition (CTRL/PD) with a False Discovery Rate or FDR<0.25 (Complete list
in Supplementary Figure 2B). The Oncogenic Signatures enriched in the PDR models
included two signatures defined by RB knockdown, suggesting the PDR models have
upregulated genes that are induced by RB knockdown. Representative GSEA plots of the RB
knockdown signatures are shown for PDR2 vs WT after PD treatment. C. GSEA Oncogenic
Signature altered kinase signatures in the LNCaP PDR models for all conditions.
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Figure 3. Integrative transcriptome and kinome profiling identifies differential MAPK stimulus
as a hallmark of CDK4/6 inhibitor resistance

A. LNCaP PDR and parental cells were treated for 24h with 0.5uM PD or control, snap
frozen and lysed. After peptide digestion, phospho-Tyrosine peptides (pY) were
immunoprecipitated, while phospho-Serine/Threonine peptides (pST) remained in the upper
fraction (see schematic, more details in Materials and Methods). Duplicates of both peptide
fractions were utilized in an unbiased phosphoproteomics approach to identify altered
phosphorylation of Tyrosine and Serine/Threonine peptides across PDR models compared to
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the parental cells, displayed by hierarchical clustering on the right. B. Kinase/Substrate
Enrichment Analysis (KSEA) defined enriched peptide motifs for phosphorylated Tyrosine
(pY) hits and mapped them to kinases that are most likely to target these motifs. This
revealed enrichment for Src and Src Homology (SH2) domain target motifs in PDR1/2
compared to parental cells (p=0.2). C. KSEA analysis for pST hits showed enrichment for
altered phosphorylation of MAPK3 and MAPK1 (ERK1/2) target motifs (p=0.05), indicative
of differential MAPK signaling.
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Figure 4. Acquired CDK4/6 inhibitor resistance promotes aggressive phenotypes
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A. LNCaP PDR and parental cells were treated for 24h with 0.5μM PD or CTRL, lysed and
immunoblotted for phospho-ERK1/2 (P-ERK1/2) and total ERK1/2 (t-ERK1/2). Results
show hyperphosphorylation of ERK1/2 in the PDR lines compared to parental cells, while
total protein levels are unchanged across the different models and conditions. These data
indicate that the MAPK pathway is activated in the PDR models. B. EGF transcript level
fold changes of LNCaP PDR1/2 relative to parental from RNAseq data (top, *q-value<0.1;
error bars: standard error) show elevated EGF mRNA, resulting in increased EGF protein
expression via Western blotting (bottom, numbers represent EGF quantification normalized
to GAPDH, relative to parental CTRL. C. A time course experiment to assess cell
proliferation via Trypan blue exclusion revealed that the PDR cells off PD selection are
hyperproliferative compared to parental cells (*Significance was determined by a Two-way
ANOVA analysis performing a multivariate comparison of mean per time point for PDR vs
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parental; p<0.0001). D. Cells were seeded in 6 replicates in serum-free media in a
Fluoroblok transwell migration (without matrigel) or invasion (with matrigel) plates and
allowed to migrate for 48h or invade for 72h to serum-rich (20%) media in the bottom of the
well. PDR cells display enhanced migratory capacity and invasion through matrigel
(*Student’s t-test: p<0.05 vs parental). E. Clonogenic capacity of the PDR and parental lines
was assessed by seeding cells at low density (5,000/well in a 6-wells plate) in media
supplemented with 0.6% agar and left to grow 3 weeks. The PDR lines displayed the ability
to grow larger 3D colonies in agar. Images (left) show representative wells of triplicates.
“+ctrl” are MAF cells with known clonogenicity. Colony sizes were determined via image
pixel counts in FIJI (see Materials and Methods), triplicates were pooled and plotted (right)
as single dots according to size (Y-axis). Line and whiskers show median and 95%
Confidence Interval (CI, *Statistical significance determined by a One-way ANOVA
compared to parental). F. Sub-cutaneous xenograft tumor growth of LNCaP PDR and
parental cells injected at 3×106 cells in the flanks of athymic nude mice (n=6 per group)
reveal accelerated tumor formation in vivo, graphed as % tumor free survival (TFS) over
time (left). *Statistical significance determined via One-way ANOVA compared to parental.
Table (right) shows reduced time to 50% tumor free survival (TFS) and enhanced overall
tumor take.
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Figure 5. CDK4/6i resistant models become reliant on activated MAPK pathway and sensitized
to MEK inhibition

A. LNCaP cells were treated 24h with 0.5 or 1μM MEK inhibitor (U0126) or CTRL and
immunoblotted for p-ERK1/2, demonstrating loss of the hyperphosphorylation of ERK1/2
observed in the LNCaP PDR models when MEK is inhibited, confirming that the MAPK
pathway is activated in the PDR models. MEK inhibition does not affect RB
hyperphosphorylation (upper band tRB) or CDK4 phosphorylation, indicating a bypass of
the RB cell cycle checkpoint. B. Cell counting via Trypan blue exclusion after 6 days of 0.5
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or 1μM U0126 treatment reveals that the PDR models are sensitized to MEK inhibition
(*significant difference compared to corresponding treatment in parental cells). C. Invasion
of PDR cells, but not parental cells, through matrigel in a Fluoroblok transwell system
decreases with a MEK inhibitor (*p<0.05 vs parental). D. Clonogenic assay shows reduction
in both size (center) and total numbers of colonies (right) formed by the PDR models,
whereas the parental cells are unresponsive to MEK inhibition (0.5μM U0128). E. Cell
counting with escalating doses of U0126 (0-0.5uM, t=6d) shows a cooperative effect with
0.5uM PD in PDR cells. F. LNCaP parental and PDR cells were injected sub-Q into the
flanks of athymic nude mice. When tumors reached ~150mm3, mice were treated with chow
laced with trametinib (TRAM). Caliper measurements revealed that, while the parental
tumors were unresponsive to the MEK inhibitor,, the PDR models are sensitized to
trametinib in vivo (error bars represent SEM).
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Figure 6. cBioportal analysis of clinical datasets reveals MAPK subfamily alterations in primary
and metastatic tumors

A. cBioportal analyses of the TCGA clinical cohort shows alterations in DNA and/or RNA
for MAPK pathway genes in 128/333 primary prostate cancer patients (38%). Similarly,
SU2C/PCF cohort reveals alterations in 71/150 patients with advanced prostate cancer
(~47%). The majority of alterations in these patient datasets are gene amplification and/or
transcriptional upregulation (~68% and ~85%, respectively). B. MAPK subfamily kinase
analysis of alterations observed in primary (blue) and metastatic (purple) showing total
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percentages per subfamily (horizontal bar graphs), and exclusive versus co-occuring
subfamily alterations (vertical bar graph, black dots indicate alteration, details per patient in
Supplementary Figure 7). C. Schematic of acquired CDK4/6 inhibitor resistance. The PDR
models presented here have acquired resistance to CDK4/6 inhibition, resulting in
proliferation and aggressive phenotypes. This acquired resistance is associated with MAPK
pathway activation, creating a delicate reliance on this pathway that is independent of the
RB cell cycle checkpoint. This MAPK activation resulted in sensitization to MEK inhibition.
EGF upregulation was observed in the PDR models, which activates the EGF Receptor
(EGFR), and likely activates MAPK signaling downstream. While CDK4/6 inhibitors fail to
block tumor growth in these models of acquired resistance, the sensitization to MEK
inhibition provides new rationale for treating cancers that have acquired resistance to
CDK4/6 inhibitors.
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